ENA lung cancer vaccine in Germany is still a matter for clinical trials, not a finished medicine. People look for one when told that the standard options are running out, expecting from the word «vaccine» a shot that prevents the disease.
In cancer medicine the word means something else. This page explains what it means, which vaccines exist, what can actually be obtained in Germany and in what order, and how this differs from standard immunotherapy. No miracle is promised and no survival figures are quoted. For standard options, see lung cancer treatment in Germany.
What a vaccine means in cancer medicine
In cancer medicine, «vaccine» covers two things: a preventive vaccine that stops a disease from starting, such as those against human papillomavirus or hepatitis B, viruses that can cause cancer, and a therapeutic vaccine for someone who already has a tumour. Lung cancer concerns only the second.
The idea: a tumour protein is shown to the immune system so that immune cells learn to recognise it and look for it throughout the body. Such a recognition mark is called an antigen, usually a protein fragment. A neoantigen arises from a mutation in the tumour and is absent from healthy cells, which makes it a good target.
This is hard: a tumour grows from the body’s own cells, which the immune system has learned to tolerate, and its surroundings dampen the response. Hence the caution, and the long list of vaccine trials that ended without a result.
The kinds under development
Kinds under development include peptide vaccines: fragments of tumour proteins given with a substance that strengthens the immune response. In non-small-cell lung cancer, the most common form, such products have been and are being tested; some failed, others are still under study.
Dendritic cell vaccines start with cells taken from the patient’s blood, which are trained in the laboratory and given back. The method is described in detail under dendritic cell therapy.
The youngest approach is individual mRNA vaccines against neoantigens: the tumour is sequenced (its genetic code is read), the mutations specific to it are selected and a product is made for that patient, whose cells then build the protein fragments from its mRNA instructions. The place of this approach is still being decided in trials, not in the standard.
What is actually available in Germany
The plain and inconvenient point: no therapeutic vaccine is approved in Germany as a standard treatment for lung cancer, so it cannot be obtained as a matter of indication.
The legal routes are a clinical trial at a university hospital or cancer centre and, more rarely, individual use outside the approved indications, which the doctor justifies in writing, or a manufacturer’s compassionate use programme (Härtefallprogramm). The German Cancer Research Center’s cancer information service also notes that such vaccines are mostly still under research, with none approved in Germany.
Private offers of an «individual cancer vaccine» for large sums outside trials do exist, with no evidence of benefit in lung cancer. The patient is entitled to ask in which trial it is used and where the results were published. Before paying, get a second opinion from a German doctor.
How a vaccine differs from the immunotherapy that is used
Checkpoint inhibitor immunotherapy is part of standard treatment in non-small-cell lung cancer, and it is not a vaccine. Checkpoints are brakes that stop the immune system attacking healthy tissue, and tumours exploit them; the drug does not teach the immune system to recognise the tumour but releases the brake on cells already there. More on lung cancer immunotherapy.
The two are sometimes combined: the vaccine should supply cells that recognise the tumour, the inhibitor should stop the tumour switching them off. This combination is also still a matter for trials.
Treatment is actually decided by histology (the tumour type under the microscope), stage, the tumour’s molecular profile (its mutations and target proteins) and the patient’s condition. Without fresh tissue and a mutation analysis, talk of vaccines has nothing to stand on. Testing is explained under lung cancer diagnostics.
How patients get into a trial
Getting into a trial starts with a review of records, so collect a complete package: histology report, molecular test results, a description of previous treatment, recent imaging, blood results and current medicines. The fuller the package, the faster the answer.
Inclusion criteria are narrow, and a refusal more often reflects previous therapy, other illnesses or a missing mutation than the cancer itself. Be prepared for there being no matching trial protocol.
How long this takes depends on the centre, the protocol and how complete the records are, so no exact time can be given. Standard treatment is not postponed while waiting for a trial: what the oncologist offers, including care that relieves symptoms, continues.
Frequently asked questions
Is there a lung cancer vaccine in Germany?
No therapeutic lung cancer vaccine is approved in Germany yet, so none can be prescribed as ordinary treatment. Such vaccines are studied in clinical trials, open only to patients who meet a specific protocol’s conditions. Nor is there yet a preventive vaccine against lung cancer.
Can a vaccine be obtained when standard options run out?
Sometimes, but only legally: through a clinical trial or, more rarely, individual use that the doctor justifies in writing. An oncologist at a specialised centre first checks the records for a suitable protocol. If there is none, the treatment the doctors offer stays the priority, not a paid vaccine without proven benefit.
Is there proof that a vaccine helps in lung cancer?
Not reliable proof yet: in trials, cancer vaccines have shown only limited benefit, so they are not standard treatment. Many earlier products disappointed; newer peptide, dendritic cell and individual mRNA vaccines are still being tested, often with immunotherapy. Promised results outside trials deserve caution.
How AlenMed arranges treatment and a trial enquiry
AlenMed has the records translated and sent to an oncologist at a specialised centre, who first states in writing what he considers appropriate at this stage of the disease; only then does the clinic issue an estimate, followed by the visa invitation, dates and an interpreter at the appointment. One such oncologist is Dr Benedikt Westphalen, who leads precision oncology, matching treatment to the tumour’s molecular profile, at the Centre for Personalised Medicine.
Ask in advance whether an open protocol exists for this diagnosis, who looks after the patient between visits and what happens if the trial does not accept them.
This material is for information and is not an offer; the treatment plan is decided by a doctor in person.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
